{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:50:34Z","timestamp":1787590234511,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/bmt.2017.16","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T14:17:55Z","timestamp":1488291475000},"page":"962-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL"],"prefix":"10.1038","volume":"52","author":[{"given":"M","family":"Kotrova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V H J","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J M","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Formankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Sedlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Stary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Trka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Fronkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"BFbmt201716_CR1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","volume":"352","author":"JJ van Dongen","year":"1998","unstructured":"van Dongen JJ, Seriu T, Panzer-Gr\u00fcmayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (London, England) 1998; 352: 1731\u20131738.","journal-title":"Lancet (London, England)"},{"key":"BFbmt201716_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/sj.leu.2404535","volume":"21","author":"VHJ van der Velden","year":"2007","unstructured":"van der Velden VHJ, Panzer-Gr\u00fcmayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706\u2013713.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/leu.2008.22","volume":"22","author":"E Fronkova","year":"2008","unstructured":"Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 2008; 22: 989\u2013997.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR4","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol 2016; 34: 2591\u20132601.","journal-title":"J Clin Oncol"},{"key":"BFbmt201716_CR5","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","volume":"92","author":"CJ Knechtli","year":"1998","unstructured":"Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92: 4072\u20134079.","journal-title":"Blood"},{"key":"BFbmt201716_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/sj.bmt.1704241","volume":"32","author":"O Krejci","year":"2003","unstructured":"Krejci O, van der Velden VHJ, Bader P, Kreyenberg H, Goulden N, Hancock J et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32: 849\u2013851.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201716_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/pbc.20794","volume":"48","author":"L Sramkova","year":"2007","unstructured":"Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 93\u2013100.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbmt201716_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3324\/haematol.10965","volume":"92","author":"O Spinelli","year":"2007","unstructured":"Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007; 92: 612\u2013618.","journal-title":"Haematologica"},{"key":"BFbmt201716_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GHR, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377\u2013384.","journal-title":"J Clin Oncol"},{"key":"BFbmt201716_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjh.12639","volume":"164","author":"A Balduzzi","year":"2014","unstructured":"Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol 2014; 164: 396\u2013408.","journal-title":"Br J Haematol"},{"key":"BFbmt201716_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, Von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the all-bfm-sct 2003 trial. J Clin Oncol 2015; 33: 1275\u20131284.","journal-title":"J Clin Oncol"},{"key":"BFbmt201716_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/leu.2010.133","volume":"24","author":"AC Lankester","year":"2010","unstructured":"Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJM, de Weger RA, Wijnen JT et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010; 24: 1462\u20131469.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","volume":"538","author":"VHJ van der Velden","year":"2009","unstructured":"van der Velden VHJ, van Dongen JJM . MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 2009; 538: 115\u2013150.","journal-title":"Methods Mol Biol"},{"key":"BFbmt201716_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VHJ van der Velden","year":"2007","unstructured":"van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604\u2013611.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/sj.leu.2404925","volume":"22","author":"VHJ van der Velden","year":"2008","unstructured":"van der Velden VHJ, Wijkhuijs JM, van Dongen JJM . Non-specific amplification of patient-specific Ig\/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia 2008; 22: 641\u2013644.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/bmt.2008.122","volume":"42","author":"E Fronkova","year":"2008","unstructured":"Fronkova E, Muzikova K, Mejstrikova E, Kovac M, Formankova R, Sedlacek P et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant 2008; 42: 187\u2013196.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201716_CR17","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120: 5173\u20135180.","journal-title":"Blood"},{"key":"BFbmt201716_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","volume":"126","author":"M Kotrova","year":"2015","unstructured":"Kotrova M, Muzikova K, Mejstrikova E, Novakova M, Bakardjieva-Mihaylova V, Fiser K et al. The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood 2015; 126: 1045\u20131047.","journal-title":"Blood"},{"key":"BFbmt201716_CR19","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","volume":"125","author":"MA Pulsipher","year":"2015","unstructured":"Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N et al. IgH-V(D)J NGS-MRD measurement pre- and early post- allo-transplant defines very low and very high risk ALL patients. Blood 2015; 125: 3501\u20133508.","journal-title":"Blood"},{"key":"BFbmt201716_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2401245","volume":"13","author":"MJ Pongers-Willemse","year":"1999","unstructured":"Pongers-Willemse MJ, Seriu T, Stolz F, d\u2019Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investiga. Leukemia 1999; 13: 110\u2013118.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR21","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJM van Dongen","year":"2003","unstructured":"van Dongen JJM, Langerak AW, Br\u00fcggemann M, Evans PAS, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257\u20132317.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR22","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood.V98.8.2456","volume":"98","author":"AW Langerak","year":"2001","unstructured":"Langerak AW, Wolvers-Tettero IL, van Gastel-Mol EJ, Oud ME, van Dongen JJ . Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 2001; 98: 2456\u20132465.","journal-title":"Blood"},{"key":"BFbmt201716_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/sj.leu.2402515","volume":"16","author":"VHJ van der Velden","year":"2002","unstructured":"van der Velden VHJ, Wijkhuijs JM, Jacobs DCH, van Wering ER, van Dongen JJM . T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 1372\u20131380.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/sj.leu.2402475","volume":"16","author":"VHJ van der Velden","year":"2002","unstructured":"van der Velden VHJ, Willemse MJ, van der Schoot CE, H\u00e4hlen K, van Wering ER, van Dongen JJM . Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928\u2013936.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/sj.leu.2401801","volume":"14","author":"OJ Verhagen","year":"2000","unstructured":"Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426\u20131435.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR26","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/sj.leu.2401246","volume":"12","author":"MJ Pongers-Willemse","year":"1998","unstructured":"Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006\u20132014.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR27","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318\u20132357.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR28","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/leu.2008.386","volume":"23","author":"M Zaliova","year":"2009","unstructured":"Zaliova M, Fronkova E, Krejcikova K, Muzikova K, Mejstrikova E, Stary J et al. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR\/ABL-positive ALL: implications for residual disease monitoring. Leukemia 2009; 23: 944\u2013951.","journal-title":"Leukemia"},{"key":"BFbmt201716_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2016","unstructured":"Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 2016; 129: 347\u2013357.","journal-title":"Blood"},{"key":"BFbmt201716_CR30","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V93.12.4079","volume":"93","author":"T Szczepanski","year":"1999","unstructured":"Szczepanski T, Pongers-willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJM, Van Wering ER et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999; 93: 4079\u20134085.","journal-title":"Blood"},{"key":"BFbmt201716_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Br\u00fcggemann","year":"2010","unstructured":"Br\u00fcggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521\u2013535.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201716","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:16:08Z","timestamp":1648062968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFbmt201716"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.16","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]},"assertion":[{"value":"18 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJMvD, VHJvdV and MB are Board members of EuroMRD (). The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}